The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Excess Deaths Associated With Tigecycline After Approval Based on Noninferiority Trials
Open accessAbstract
BACKGROUND: On the basis of noninferiority trials, tigecycline received Food and Drug Administration (FDA) approval in 2005. In 2010, the FDA warned in a safety communication that tigecycline was associated with an increased risk of death. METHODS: PubMed, EMBASE, Scopus, and ClinicalTrials.gov were searched using the terms "tigecycline" and "randomized controlled trial (RCT)" through April 2011. Excess deaths and noncure rates for both approved and nonapproved indications were examined using meta-analysis. RESULTS: Ten published and 3 unpublished studies met inclusion criteria (N = 7434). No significant heterogeneity was seen for mortality (I(2 )= 0%; P = .99) or noncure rates (I(2 )= 25%; P = .19). Across randomized controlled trials, tigecycline was associated with increased mortality (risk difference [RD], 0.7%; 95% confidence interval [CI], 0.1%-1.2%; P = .01) and noncure rates (RD, 2.9%; 95% CI, 0.6%-5.2%; P = .01). Effects were not isolated to type of infection or comparator antibiotic regimen, and the impact on survival remained significant when limited to trials of approved indications (I(2 )= 0%; RD, 0.6%; P = .04). A pooled analysis of the 5 trials completed by early 2005 before tigecycline was approved would have demonstrated a similar harmful effect of tigecycline on survival (I(2 )= 0%; RD, 0.7%; P = .06). CONCLUSIONS: Pooling noninferiority studies to examine survival may help ensure the safety and efficacy of new antibiotics. The association of tigecycline with excess deaths and noncure includes indications for which it is approved and marketed. Tigecycline cannot be relied on in serious infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
Sterne, J. A. C., Sutton, A. J., Ioannidis, J. P. A., Terrin, N., Jones, D. R., Lau, J., Carpenter, J., Rucker, G., Harbord, R. M., Schmid, C. H., et al. (2011) · BMJ · doi:10.1136/bmj.d4002 · Cited by 7,709 · cited 1×
“Egger’s regression [33], which could have limited power [34].”
BackgroundLiu, C., Bayer, A., Cosgrove, S. E., Daum, R. S., Fridkin, S. K., Gorwitz, R. J., Kaplan, S. L., Karchmer, A. W., Levine, D. P., Murray, B. E., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq146 · Cited by 4,191
(2000) · Queen Mary Research Online (Queen Mary University of London) · Cited by 1,795
Practice Guidelines for the Diagnosis and Management of Skin and Soft-Tissue Infections
Stevens, D. L., Bisno, A. L., Chambers, H. F., Everett, E. D., Dellinger, P., Goldstein, E. J. C., Gorbach, S. L., Hirschmann, J. V., Kaplan, E. L., Montoya, J. G., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/497143 · Cited by 1,602
Solomkin, J. S., Mazuski, J. E., Bradley, J. S., Rodvold, K. A., Goldstein, E. J. C., Baron, E. J., O'Neill, P. J., Chow, A. W., Dellinger, E. P., Eachempati, S. R., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/649554 · Cited by 1,558
The Promise and Problems of Meta-Analysis
Bailar, J. C. (1997) · New England Journal of Medicine · doi:10.1056/nejm199708213370810 · Cited by 402
Antibiotics for acute otitis media: a meta-analysis with individual patient data
Rovers, M. M., Glasziou, P., Appelman, C. L., Burke, P., McCormick, D. P., Damoiseaux, R. A., Gaboury, I., Little, P., & Hoes, A. W. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69606-2 · Cited by 333
The Glycylcyclines: A Comparative Review with the Tetracyclines
Zhanel, G. G., Homenuik, K., Nichol, K., Noreddin, A., Vercaigne, L., Embil, J., Gin, A., Karlowsky, J. A., & Hoban, D. J. (2004) · Drugs · doi:10.2165/00003495-200464010-00005 · Cited by 306
Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose
Rodvold, K. A., Gotfried, M. H., Cwik, M., Korth-Bradley, J. M., Dukart, G., & Ellis-Grosse, E. J. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl403 · Cited by 304
Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia
Freire, A. T., Melnyk, V., Kim, M. J., Datsenko, O., Dzyublik, O., Glumcher, F., Chuang, Y.-C., Maroko, R. T., Dukart, G., Cooper, C. A., et al. (2010) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2010.05.012 · Cited by 284
Efficacy and safety of tigecycline: a systematic review and meta-analysis
Yahav, D., Lador, A., Paul, M., & Leibovici, L. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr242 · Cited by 266
Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis
Tasina, E., Haidich, A.-B., Kokkali, S., & Arvanitidou, M. (2011) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70177-3 · Cited by 260
Sequential methods for random‐effects meta‐analysis
Higgins, J. P. T., Whitehead, A., & Simmonds, M. (2011) · Statistics in Medicine · doi:10.1002/sim.4088 · Cited by 258
Tigecycline: A New Glycylcycline for Treatment of Serious Infections
Noskin, G. A. (2005) · Clinical Infectious Diseases · doi:10.1086/431672 · Cited by 226
Non-inferiority trials are unethical because they disregard patients' interests
Garattini, S., & Bertele', V. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61604-3 · Cited by 197
Breedt, J., Teras, J., Gardovskis, J., Maritz, F. J., Vaasna, T., Ross, D. P., Gioud-Paquet, M., Dartois, N., Ellis-Grosse, E. J., & Loh, E. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.11.4658-4666.2005 · Cited by 192
Cai, Y., Wang, R., Liang, B., Bai, N., & Liu, Y. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01402-10 · Cited by 189
The Pharmacokinetic and Pharmacodynamic Profile of Tigecycline
Meagher, A. K., Ambrose, P. G., Grasela, T. H., & Ellis‐Grosse, E. J. (2005) · Clinical Infectious Diseases · doi:10.1086/431674 · Cited by 188
(2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir353 · Cited by 172
Oliva, M. E., Rekha, A., Yellin, A. E., Pasternak, J., Campos, M., Rose, G. M., Babinchak, T., Ellis‐Grosse, E. J., Loh, E., & the 301 Study Group (2005) · BMC Infectious Diseases · doi:10.1186/1471-2334-5-88 · Cited by 153
Sacchidanand, S., Penn, R. L., Embil, J. M., Campos, M. E. D. S., Curcio, D., Ellis‐Grosse, E. J., Loh, E., & Rose, G. M. (2005) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2005.05.003 · Cited by 152
Florescu, I., Beuran, M., Dimov, R., Razbadauskas, A., Bochan, M. R., Fichev, G., Dukart, G., Babinchak, T., Cooper, C. A., Ellis‐Grosse, E. J., et al. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn250 · Cited by 134
O’Riordan, W. D., Mehra, P., Manos, P., Kingsley, J., Lawrence, L. E., & Cammarata, S. (2014) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2014.10.009 · Cited by 102
Bergallo, C., Jasovich, A., Teglia, O., Oliva, M. E., Lentnek, A. L., de Wouters, L., Zlocowski, J. C., Dukart, G., Cooper, A., & Mallick, R. (2008) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2008.09.001 · Cited by 94
Gardiner, D., Dukart, G., Cooper, A., & Babinchak, T. (2009) · Clinical Infectious Diseases · doi:10.1086/648720 · Cited by 91
Boucher, H. W. (2010) · Clinical Infectious Diseases · doi:10.1086/647937 · Cited by 69
Towfigh, S., Pasternak, J., Poirier, A., Leister, H., & Babinchak, T. (2010) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2010.03122.x · Cited by 55
Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia
the 313 Study Group, Tanaseanu, C. M., Milutinovic, S., Calistru, P. I., Strausz, J., Zolubas, M., Chernyak, V., Dartois, N., Castaing, N., Gandjini, H., et al. (2009) · BMC Pulmonary Medicine · doi:10.1186/1471-2466-9-44 · Cited by 55
Issues in Noninferiority Trials: The Evidence in Community‐Acquired Pneumonia
Fleming, T. R., & Powers, J. H. (2008) · Clinical Infectious Diseases · doi:10.1086/591390 · Cited by 53
Chen, Z., Wu, J., Zhang, Y., Wei, J., Leng, X.-S., Bi, J., Li, R., Yan, L., Quan, Z., Chen, X., et al. (2010) · BMC Infectious Diseases · doi:10.1186/1471-2334-10-217 · Cited by 45
Noninferiority and equivalence trials: deciphering ‘similarity’ of medical interventions
Powers, J. H. (2008) · Statistics in Medicine · doi:10.1002/sim.3138 · Cited by 41
Guideline: Appropriate use of tigecycline
Brink, A. J., Bizos, D., Boffard, K. D., Feldman, C. H., Grolman, D. C., Pretorius, J., Richards, G. A., Senekal, M., Steyn, E., & Welkovic, N. (2010) · South African Medical Journal · doi:10.7196/samj.4109 · Cited by 40
Powers, J. H. (2007) · Clinical Infectious Diseases · doi:10.1086/519253 · Cited by 27
Falagas, M. E., & Metaxas, E. I. (2009) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.09.73 · Cited by 17
Cited by
Antimicrobial Resistance in ESKAPE Pathogens
De Oliveira, D. M. P., Forde, B. M., Kidd, T. J., Harris, P. N. A., Schembri, M. A., Beatson, S. A., Paterson, D. L., & Walker, M. J. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00181-19 · Cited by 2,078
Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges
Wong, D., Nielsen, T. B., Bonomo, R. A., Pantapalangkoor, P., Luna, B., & Spellberg, B. (2017) · Clinical Microbiology Reviews · doi:10.1128/cmr.00058-16 · Cited by 1,170
Kadri, S. S., Adjemian, J., Lai, Y. L., Spaulding, A. B., Ricotta, E., Prevots, D. R., Palmore, T. N., Rhee, C., Klompas, M., Dekker, J. P., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy378 · Cited by 605
Self-citationThe Surgical Infection Society Revised Guidelines on the Management of Intra-Abdominal Infection
Mazuski, J. E., Tessier, J. M., May, A. K., Sawyer, R. G., Nadler, E. P., Rosengart, M. R., Chang, P. K., O'Neill, P. J., Mollen, K. P., Huston, J. M., et al. (2017) · Surgical Infections · doi:10.1089/sur.2016.261 · Cited by 573
Antibiotic resistance in Enterobacteriaceae: mechanisms and clinical implications
Iredell, J., Brown, J., & Tagg, K. (2016) · BMJ · doi:10.1136/bmj.h6420 · Cited by 392
Metadata
- Authors
- Prasad, P., Sun, J., Danner, R. L., & Natanson, C.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-03-30
- Volume
- 54
- Issue
- 12
- Pages
- 1699-1709
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2104747240
- Cited by
- 298
- References
- 36
- FWCI
- 49.23
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.